We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Edwards Lifesciences

Manufactures tissue replacement heart valves and valve repair products, hemodynamic monitoring devices read more Featured Products: More products

Download Mobile App




Tiny Shunt Device Alleviates Heart Failure Symptoms

By HospiMedica International staff writers
Posted on 04 Sep 2023

Heart failure ranks as the leading cause of hospital admissions worldwide. More...

This chronic ailment occurs when the heart muscle functions inefficiently. Among heart failure cases, about half fall under heart failure with preserved ejection fraction (HFpEF), characterized by stiffening of the heart muscle, impairing proper relaxation and filling. This progression often leads to symptoms like shortness of breath, fatigue, swelling in the legs and ankles, and exercise challenges. Now, a novel investigational device relieves pressure in the left side of the heart, thereby reducing symptoms of heart failure such as shortness of breath.

Atrial fibrillation and a leaky mitral valve are frequently observed in heart failure patients. When conventional approaches like medications and lifestyle adjustments fall short, corrective procedures may be necessary that require the interatrial septum for the catheter’s entry. The Apture transcatheter shunt system from Edwards Lifesciences (Irvine, CA, USA) offers an innovative solution to offload the left side of the heart while preserving the septum for future interventions. During the procedure, doctors insert a catheter through a neck vein, providing access to the heart. The tiny shunt device is implanted between the coronary sinus vein and the left atrium. This placement maintains the interatrial septum, the wall dividing the upper chambers of the heart. Following the successful implantation of the device in an early feasibility study in April 2022, researchers have now enrolled the world's first patient in a clinical trial to assess its effectiveness. The trial, known as ALT-FLOW II, is a randomized, double-blind study that will involve a total of 100 patients across 30 investigational sites.

Related Links:
Edwards Lifesciences


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Cervical Seal
Omni Lok
New
Complete Hip System
Taperloc Complete Hip System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.